Is motixafortide FDA-approved, and what does the research show?

What is motixafortide?

Motixafortide is a medicine used to collect a patient's blood-forming stem cells before a transplant ². It is sold as Aphexda, and its FDA label calls it "a hematopoietic stem cell mobilizer" ². Hematopoietic stem cells are the cells in the bone marrow that give rise to new blood cells ¹, ². A mobilizer moves them out of the marrow and into the bloodstream, where they can be collected ².

The label describes the compound as "a synthetic, cyclic peptide composed of a sequence of amino acids" ². Amino acids are the building blocks of proteins, and "cyclic" means part of the chain is closed into a ring ². The published trial report also uses its development code, BL-8040 ¹.

Motixafortide is not a wellness, weight-loss or performance peptide. It is a specialist medicine for people with multiple myeloma, a blood cancer, who are preparing for a transplant of their own stem cells ¹, ². The trial report says such a transplant, given after high-dose chemotherapy, plays a central role in treating multiple myeloma ¹. Its effectiveness depends in part on collecting enough stem cells beforehand ¹.

Is motixafortide FDA-approved?

Yes. FDA approved Aphexda (motixafortide) on September 8, 2023, under new drug application (NDA) 217159 ³. Its marketing status is "Prescription" as of November 9, 2026, the date of the Drugs@FDA record's data ³. The record lists one product, a powder for injection under the skin ³.

The label gives one indication ². Aphexda "is indicated in combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma" ². Filgrastim is a form of G-CSF, granulocyte colony-stimulating factor ¹, ². The trial report calls G-CSF the standard agent for moving stem cells into the blood ¹. "Peripheral blood" is the blood in circulation, and "autologous" means the transplant uses the patient's own cells ¹, ².

So the approval covers one step of one procedure, in one group of patients, and always alongside filgrastim ². The label adds that Aphexda "is not intended for HSC mobilization and harvest in patients with leukemia," HSC being its short form for hematopoietic stem cell ². It also says safety and effectiveness "have not been established in pediatric patients" ². The label names no use for weight, metabolism, muscle, aging or athletic performance ².

See the FDA status of every peptide, updated weekly.

How does motixafortide work?

Blood-forming stem cells carry a receptor, a docking protein on the cell surface, called CXCR4 ². Its natural partner is a signal molecule called SDF-1α, or CXCL12 ². The label says the pair "play a role in the trafficking and homing of human hematopoietic stem cells to the marrow compartment" ². Once the cells are in the marrow, CXCR4 "can help anchor these cells to the marrow matrix" ².

Motixafortide blocks that anchor. The label says it "is an inhibitor of the C-X-C Motif Chemokine Receptor 4 (CXCR4) and blocks the binding of its cognate ligand," the partner molecule ². Stem cells then move into the bloodstream: the label reports raised counts of circulating stem cells "in mice, rats, dogs, and humans" ². White blood cell counts rise too, which the label calls leukocytosis ².

CD34 is the surface marker that clinicians most often use to identify these stem cells, and cells that carry it are written CD34+ ¹. Studied in people: in healthy volunteers given motixafortide alone, blood counts of CD34+ cells peaked 16 hours after the dose ². They were still well above the starting level at 24 hours ².

In GENESIS, the randomized trial of 122 patients with multiple myeloma, the blood CD34+ count rose a median 6.7-fold over 24 hours with motixafortide and filgrastim ². With placebo and filgrastim it rose 1.5-fold ².

What does the research show?

One trial, called GENESIS, is the label's efficacy evidence, and it measured whether patients reached a stem cell collection goal ². It was a phase 3 trial, the large late stage that precedes an approval, run at 18 sites in five countries ¹. The report lists its funding as BioLineRx, Ltd. and two U.S. National Cancer Institute grants ¹. It enrolled 122 adults with multiple myeloma, in complete or partial response to earlier treatment, who were undergoing their first transplant of their own stem cells ¹. Patients who had had a transplant before, or whose earlier stem cell collection had failed, were excluded ¹.

The trial was randomized, double-blind and placebo-controlled ¹, ². Patients were assigned by chance, two to one, to motixafortide (80 patients) or to a placebo, a dummy injection (42 patients) ¹, ². Neither the patients nor their clinicians knew which they had received ¹. Everyone received filgrastim each morning for four days, then one injection of motixafortide or placebo that evening ². Collection by apheresis, the procedure that harvests stem cells from the bloodstream, began the next day ¹, ².

The goal was to collect at least 6 million CD34+ cells for each kilogram of the patient's body weight ¹, ². The cells were counted by local laboratories and by a central laboratory ¹, ². The authors report results favoring motixafortide by both sets of counts, each statistically significant, meaning unlikely to arise by chance ¹.

The label uses the central laboratory's counts ². By those counts, 67.5 percent of the motixafortide arm reached the goal in up to two apheresis sessions after a single dose ². In the placebo arm, 9.5 percent did ². The label gives the adjusted difference between the arms as "56.8%," which is 56.8 percentage points (p < 0.0001), a result very unlikely to arise by chance ².

In a single session, by the same central counts, 63.8 percent of the motixafortide arm reached the goal, against 2.4 percent of the placebo arm ². For a lower target of 2 million cells per kilogram in one session, the figures were 87.5 percent and 38.1 percent ². The trial report says a minimum of 2 million cells per kilogram is necessary for a transplant ¹.

The published report gives the local laboratories' counts, on which clinical decisions in the trial were made ¹. By those counts, 92.5 percent of the motixafortide arm met the goal within two apheresis days, against 26.2 percent of the placebo arm ¹. The odds ratio, which compares the odds of success in the two arms, was 53.3 ¹. Its 95 percent confidence interval, the range that plausibly holds the true value, ran from 14.12 to 201.33 ¹. In one apheresis day the figures were 88.8 percent and 9.5 percent ¹.

The trial stopped early. Its plan called for 177 patients, and a planned interim analysis was run after 122 were enrolled ¹. An independent monitoring committee then recommended halting the study because the efficacy result favored motixafortide ¹.

What the trial did not show is a better transplant. Engraftment, the recovery of blood cell counts after the transplant, took about as long in both arms ¹, ². Neutrophils, a kind of white blood cell, recovered in a median of 12 days in each arm ¹. Platelets recovered in a median of 18 days with motixafortide and 17 days with placebo ¹. Progression-free and overall survival were "comparable between the two cohorts" ¹.

The authors write that the study was not designed to test whether infusing more cells changes clinical outcomes ¹. The trial compared motixafortide with placebo, not with plerixafor, an older drug that blocks the same receptor ¹. The authors write that randomized trials comparing the available regimens in patients on current myeloma therapy are lacking ¹.

What are the side effects?

The label's safety figures come from GENESIS ². They cover 92 patients who received at least one dose of motixafortide with filgrastim, and 42 who received placebo with filgrastim ². That is 12 more than the 80 randomized to motixafortide ¹, ², and ClinicalTrials.gov lists 12 patients in the trial's lead-in part ⁴. Injection site reactions were the most common: 73 percent of the motixafortide group against 5 percent of the placebo group ². They included pain, redness and itching at the site, and the label rates the worst reaction as severe in 9 percent of the 92 ².

Itching (pruritus) was reported by 38 percent against none, flushing by 33 percent against none, and hives (urticaria) by 14 percent against none ². Back pain was reported by 21 percent against 17 percent ². Serious adverse reactions occurred in 5.4 percent of patients receiving motixafortide with filgrastim ². The label lists them as "vomiting, injection site reaction, hypersensitivity reaction, injection site cellulitis, hypokalemia and hypoxia" ². Hypokalemia is low blood potassium, and hypoxia is low oxygen ².

The trial report counts adverse events of any cause, in its own 80 and 42 randomized patients ¹. It found them in 93.8 percent of the motixafortide arm and 83.3 percent of the placebo arm ¹. Events of grade 3, meaning severe, occurred in 27.5 percent and 4.8 percent ¹. Bone pain was more common with placebo and filgrastim, at 31.0 percent against 17.5 percent ¹. No grade 4 events or deaths occurred during the mobilization period ¹.

The label's one contraindication is "a history of serious hypersensitivity reactions to motixafortide" ². Its first warning is anaphylactic shock, a life-threatening allergic reaction, which "occurred in 0.7% of APHEXDA-treated patients in clinical studies (n=407)" ². It came on between 5 and 30 minutes after the injection ². Other allergic (hypersensitivity) reactions occurred in 7.6 percent of motixafortide-treated patients in GENESIS ².

The label tells clinicians to give the drug "only in a setting where personnel and therapies are immediately available for the treatment of anaphylaxis and other systemic reactions" ². It calls for every patient to receive premedication, medicines given before the injection: "an H1-antihistamine, an H2 blocker, and a leukotriene inhibitor" ². These are two kinds of antihistamine and a third kind of allergy medicine. The label also calls for one hour of monitoring after the injection ². Patients taking "negative chronotropic drugs (e.g., beta blockers)," which slow the heart rate, "may be more at risk for hypotension in case of hypersensitivity reaction," hypotension being low blood pressure ².

Other warnings concern what the drug releases from the marrow ². In leukemia it "may cause mobilization of leukemic cells and subsequent contamination of the apheresis product" ². In its approved use, "tumor cells may be released from the marrow and subsequently collected in the leukapheresis product," and "The effect of potential reinfusion of tumor cells has not been well-studied" ². The label also tells clinicians to monitor white blood cell counts ².

Since approval, "injection site necrosis, injection site ulcer" have been reported, meaning tissue death and open sores ². Because the reports are voluntary, the label says their frequency cannot always be reliably estimated ².

On pregnancy the label says, "Based on its mechanism of action, APHEXDA can cause fetal harm when administered to a pregnant woman" ². It has no data from pregnant women and no animal reproduction studies of motixafortide ². It advises effective contraception during treatment and for 8 days after the final dose, and says breastfeeding is not recommended over the same period ².

The label also reports an effect on the heart's rhythm: "A thorough QT study in 38 healthy volunteers showed APHEXDA prolongs the QTcI interval in a concentration-dependent fashion" ². The QT interval is the time the heart's electrical system takes to reset between beats, and QTcI is that interval corrected for each person's heart rate ². The mean placebo-corrected change was 11 milliseconds (90 percent CI 8 to 14) at 1.7 times the peak blood level of the highest recommended dose ².

In sport

Motixafortide is not named on the 2026 Prohibited List of WADA, the World Anti-Doping Agency ⁵. Section S2 of the list covers peptide hormones, growth factors, related substances and mimetics, and it names neither motixafortide nor CXCR4 inhibitors ⁵. No other section names them ⁵.

What JumpstartMD offers

JumpstartMD does not prescribe motixafortide. Our peptide library covers it so you have the facts on its FDA status and the evidence, current as of November 10, 2026.

Ready to talk?

Book FREE Consultation

Share your details and a JumpstartMD team member will reach out shortly. Or call 408.478.3496 for your free, no-obligation consultation.

Share your details and a JumpstartMD team member will reach out when we open.

Disclaimer

Compounded medications are not FDA-approved, and FDA does not review their safety, effectiveness, or quality before they are marketed. A licensed clinician decides after an evaluation whether a peptide is appropriate for you, and not every patient will qualify.